- Home
- APRE vs TOVX Comparison
APRE vs TOVX Comparison
Compare APRE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- TOVX
- Stock Information
- Founded
- APRE 2006
- TOVX 2001
- Country
- APRE United States
- TOVX United States
- Employees
- APRE N/A
- TOVX N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- TOVX Health Care
- Exchange
- APRE Nasdaq
- TOVX Nasdaq
- Market Cap
- APRE 6.9M
- TOVX 7.3M
- IPO Year
- APRE 2019
- TOVX 2006
- Fundamental
- Price
- APRE $1.16
- TOVX $0.24
- Analyst Decision
- APRE Strong Buy
- TOVX Hold
- Analyst Count
- APRE 1
- TOVX 1
- Target Price
- APRE $20.00
- TOVX N/A
- AVG Volume (30 Days)
- APRE 84.3K
- TOVX 3.9M
- Earning Date
- APRE 11-12-2025
- TOVX 11-12-2025
- Dividend Yield
- APRE N/A
- TOVX N/A
- EPS Growth
- APRE N/A
- TOVX N/A
- EPS
- APRE N/A
- TOVX N/A
- Revenue
- APRE $488,239.00
- TOVX N/A
- Revenue This Year
- APRE N/A
- TOVX N/A
- Revenue Next Year
- APRE N/A
- TOVX N/A
- P/E Ratio
- APRE N/A
- TOVX N/A
- Revenue Growth
- APRE N/A
- TOVX N/A
- 52 Week Low
- APRE $1.08
- TOVX $0.20
- 52 Week High
- APRE $5.00
- TOVX $2.08
- Technical
- Relative Strength Index (RSI)
- APRE 37.51
- TOVX 40.35
- Support Level
- APRE $1.08
- TOVX $0.20
- Resistance Level
- APRE $1.28
- TOVX $0.30
- Average True Range (ATR)
- APRE 0.09
- TOVX 0.02
- MACD
- APRE -0.01
- TOVX -0.00
- Stochastic Oscillator
- APRE 30.53
- TOVX 33.95
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.